KEAP1 and autoimmune hepatitis: A study using concanavalin A (Con A)-induced autoimmune hepatitis (AIH) model in mice verified the pharma-cological activity of KM in steatohepatopathy, KM activated the Nrf2 pathway, upregulated the expression of antioxidant factors HO-1 and Nrf2 and downregulated the expression of Keap1.